B.C. Industry News
Biotechnology Focus – Qu Biologics opens Crohn’s disease clinical trial to U.S. participants
February 18, 2014
Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to â€œrebootâ€ the body’s innate immune system, announces its Crohn’s disease clinical trial is now accepting participants from the U.S.
â€œSignificant patient interest from the United States in our Crohn’s disease clinical trial prompted us to open the trial to Americans,â€ said Dr. Hal Gunn, CEO of Qu Biologics. Enrollment into the trial is already underway he added.
Sixty adults with active moderate-to-severe Crohn’s disease are being recruited to evaluate Qu Biologics’ investigational new treatment, QBECO SSI, for Crohn’s disease. A maximum of 30 U.S. patients will be allowed to participate in this Phase 1/2 Crohn’s disease research trial, located in Vancouver, Canada. The main purpose of the study is to test whether this investigational treatment is safe and effective for the treatment of Crohn’s disease.
Prior to this formal clinical trial, ten patients with Crohn’s disease were treated with QBECO SSI in a compassionate use program. All ten patients reported improvement in symptoms while on SSI treatment. Seven of the ten patients reported full resolution of clinical symptoms with a course of SSI treatment of three months or more. Four of these patients have had sustained clinical remission after discontinuing all medications including SSI treatment. The longest case of clinical remission reported is still ongoing after more than three and a half years. These previous ten patients were treated under a compassionate use program, not a controlled blinded clinical trial, and therefore these results do not provide proof of benefit.
Anyone interested in participating in the Crohn’s disease clinical trial can take a pre-screening questionnaire atwww.qucrohnstrial.com.